SHUKRA
MEDTECH LIMITED
(Formerly known as Shukra Pharmaceuticals Limited)

November 04, 2026

To,
The Listing Compliance Department
BSE Limited
P. J. Towers, Dalal Street
Mumbai – 400001
Scrip Code: 524632

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Symbol: SHUKRAPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on November 04, 2026 - Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

In continuation of our intimation dated October 23, 2026 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held on November 4, 2026, which commenced at 06.30 p.m. and concluded at 8.30 p.m., inter alia, considered and approved the following:

1. The Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2026, as recommended by the Audit Committee;

   Pursuant to Regulation 33 and other applicable regulations of the Listing Regulations, we enclose the unaudited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2026 along with the Limited Review Reports issued by the Statutory Auditors thereon, are enclosed herewith.

2. Reviewed the other business of the company.

You are requested to take the above information on records and disseminate the same on your website.

Thanking you,
Yours faithfully,

For Shukra Medtech Limited
(Formerly known as Shukra Pharmaceuticals Limited)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd979797 6bc421cc9df8e8485c129a31d99a204d3e4, pseudonym=5d8b198923c743009cfd88f8b0069402, 2.5.4.20=027313636f2560213d31d8d522de3c70d17f63b0821 5cc5628399fab337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:31:52 +05'30'

Dakshesh Shah
Director
DIN: 00561666

SHUKRA MEDTECH LIMITED Reg.No.- 019079

Encl as above

CIN : L24231GJ1993PLC019079

SHUKRA MEDTECH LIMITED

(Formerly known as Shukra Pharmaceuticals Limited)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income from Operations**						
I	Revenue from Operations	4,420.38	2,352.23	587.74	6,772.61	1,126.85	5,670.61
II	Other Income	57.20	53.97	171.26	111.17	282.23	458.48
	Total Income from Operations (I+II)	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,129.10**
2	**Expenses**						
	(a) Cost of materials consumed	1,598.58	125.46	1,080.81	1,724.04	955.96	1,945.02
	(b) Purchase of Stock-in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	-	(279.00)	(880.33)	(279.00)	(678.45)	(360.12)
	(d) Employee Benefit Expenses	127.22	241.53	219.33	368.75	401.82	703.72
	(e) Finance Cost	33.22	42.95	28.50	76.17	55.31	109.30
	(f) Depreciation & Amortisation Expenses	112.47	107.40	80.92	219.87	159.64	344.27
	(g) Other Expenses	493.24	143.63	209.93	636.87	357.64	509.62
	Total Expenses	**2,364.73**	**381.97**	**739.16**	**2,746.70**	**1,251.92**	**3,251.81**
3	**Profit before Tax (1-2)**	**2,112.85**	**2,024.23**	**19.84**	**4,137.08**	**157.16**	**2,877.29**
4	**Tax Expenses**						
	I. Current Tax	538.39	516.82	-	1,055.21	40.59	732.27
	II. Deferred Tax	(26.74)	4.43	(217.96)	(22.31)	(224.20)	(221.93)
	II. Tax of Earlier Year	-	-	-	-	-	162.15
5	**Net Profit for the period / year (3-4)**	**1,601.20**	**1,502.98**	**237.81**	**3,104.18**	**340.77**	**2,204.79**
6	**Other Comprehensive Income (net off Tax)**						
	Remeasurement of defined benefit plans	-	-	-	-	-	(8.72)
7	**Total Comprehensive Income for the period / year (6+7)**	**1,601.20**	**1,502.98**	**237.81**	**3,104.18**	**340.77**	**2,196.08**
8	**Paid up Equity Share Capital**	**4,407.87**	**4,378.79**	**4,378.79**	**4,407.87**	**4,378.79**	**4,378.79**
9	**Other Equity excluding revaluation reserve as at 31st March**	-	-	-	-	-	**4,065.80**
10	**Face Value of Equity Shares**	**1.00**	**1.00**	**1.00**	**1.00**	**1.00**	**1.00**
11	**Earnings per Share (of ₹ 1/- each) :**						
	(a) Basic - ₹	**0.36**	**0.34**	**0.05**	**0.71**	**0.08**	**0.50**
	(b) Diluted - ₹	**0.36**	**0.34**	**0.05**	**0.71**	**0.08**	**0.50**

NOTES:

1. The above Unaudited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on November 04, 2026.
2. The Unaudited Standalone Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Standalone Financial Results.
3. The Unaudited Standalone Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the half year ended September 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on September 30,
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.
7. During the half year ended September 30, 2026, the Company has converted the convertible warrants issued on a preferential basis in an earlier period into equity shares. Accordingly, the equity share capital of the Company has increased pursuant to the said conversion.
8. The name of the Company has been changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited with effect from October 12, 2026.

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK JIVRAJ PARK ROAD AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b971e2035fcd0797976bc421cc9df8b4851c29a31d99a204d3e4, pseudonym=5d8b198923c743009c6888f8b0069402, 2.5.4.20=b2313630256021d31d8d522de3c70d1761b0821 5cc5628399da1537751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:32:11 +05'30'

Dakshesh Shah
Director
DIN : 00561666

Place: Ahmedabad
Date: November 04, 2026

Unaudited Standalone Statement of Assets and Liabilities as at September 30, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	2,090.74	2,172.31
Capital work-in-progress	2,608.68	1,190.70
Investment	8.25	3.40
	4,707.67	**3,366.41**
Current assets		
Inventories	2,341.55	1,390.34
Financial assets		
(i) Trade receivables	3,871.13	2,294.76
(ii) Loans & Advances	530.25	223.09
(iii) Cash and cash equivalents	1,093.93	591.63
Other current assets	5,280.80	3,875.16
	13,117.66	**8,374.98**
Total Assets	**17,825.33**	**11,741.39**
Equity and liabilities		
Equity		
Equity share capital	4,407.87	4,378.79
Other equity	7,916.47	4,065.80
Money received against share warrants	67.02	538.66
Total Equity	**12,391.36**	**8,983.25**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	963.08	319.29
Deferred tax liabilities (net)	96.82	119.12
Long term provisions	33.27	11.44
	1,093.17	**449.85**
Current liabilities		
Financial liabilities		
(i) Borrowings	1,182.66	182.66
(ii) Trade payables	1,270.64	1,006.50
Other current liabilities	84.75	365.60
Short term provision	1,802.75	753.53
	4,340.80	**2,308.29**
Total liabilities	**5,433.97**	**2,758.14**
Total equity and liabilities	**17,825.33**	**11,741.39**

Place: Ahmedabad
Date: November 04, 2026

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, cn=Personal, serialNumber=3ba36a23be6b9f1e2035fcd979797dbc421cc9d89e8495c129a31d99e2d4d3e4, pseudonym=5d8b7d6922c74309cfd888fdb0694022,2.5.4.20=f2731363f2566213d51d8d522de3c7d417f63bd8215cc5626399fda337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:32:28 +05'30'

Dakshesh Shah
Director
DIN : 00561666

CIN : L24231GJ1993PLC019079

Unaudited Standalone Statement of Cash Flows for the period ended September 30, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	Half year ended September 30, 2026 (Unaudited)	Half year ended September 30, 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax as per statement of profit and loss	4,137.08	157.16
Adjustments for:		
Depreciation and amortisation	219.87	159.64
Interest income	(23.39)	(70.73)
Interest expense	57.03	49.09
Operating profit before working capital changes	**4,390.59**	**295.16**
Movements in working capital :		
(Increase)/decrease in trade receivables	(1,576.37)	457.68
(Increase)/decrease in inventories	(951.21)	(594.27)
(Increase)/decrease in other assets	(1,712.79)	166.74
Increase/(decrease) in trade payables	264.14	(94.16)
Increase/(decrease) in other liabilities	(265.01)	70.68
Cash generated from operations	**149.35**	**301.83**
Direct taxes (paid)/refund (net)	-	-
Net cash generated from operating activities (A)	**149.35**	**301.83**
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances	(1,556.28)	(112.12)
Interest received	23.39	70.73
Investment in subsidiary	(4.85)	-
Net cash used in investing activities (B)	**(1,537.74)**	**(41.39)**
Cash flows from financing activities		
Proceeds from / (repayment of) borrowings	1,643.80	(43.51)
Proceeds from issue of share capital	775.56	-
Money received against share warrants	(471.64)	-
Interest paid	(57.03)	(49.09)
Dividend paid	-	(43.79)
Net cash generated from / (used in) financing activities (C)	**1,890.69**	**(136.39)**
Net increase in cash & cash equivalents (A + B + C)	502.30	124.06
Cash and cash equivalents at the beginning of the period	591.63	1,211.77
Cash and cash equivalents at the end of the period	**1,093.93**	**1,335.82**
Notes:		
Cash on hand	7.76	5.99
Balances with scheduled bank	1,086.17	1,329.83
Cash and Cash Equivalents at the end of the period	**1,093.93**	**1,335.82**

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

2)The figures for the previous period /year have been regrouped/ reclassified , whenever necessary.

Place: Ahmedabad
Date: November 04, 2026

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380001, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a235be6b9f1e20355cd97979760c421cc9d8e6485c129a1d99a204d3e4, pseudonym=5d8b7d9823c743009c6886f80d069402, 2.5.4.20=0279136325602f13d11d8d522de9c70d17f63b882155c562859f9bb162771d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:52:45 +05'30'

Dakshesh Shah
Director
DIN : 00561666

SHUKRA MEDTECH LIMITED

(Formerly known as Shukra Pharmaceuticals Limited)

UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	9/30/2026 (Unaudited)	6/30/2026 (Unaudited)	9/30/2025 (Unaudited)	9/30/2026 (Unaudited)	9/30/2025 (Unaudited)	3/31/2026 (Audited)
01. Segment Revenue						
Net Sales/income from each segment						
(i) Pharamaceutical segment	3,226.93	2,406.20	759.00	5,633.13	1,409.08	6,129.10
(ii) Medtech segment	1,250.65	-	-	1,250.65	-	-
Total Segment Revenue	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,129.10**
Less: Inter Segment Revenue	-	-	-	-	-	-
Revenue From Operation	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,129.10**
02. Segment Results						
Profit/Loss before tax and interest from each segment						
(i) Pharamaceutical segment	1,836.41	2,067.18	48.34	3,903.59	212.47	2,986.59
(ii) Medtech segment	309.66	-	-	309.66	-	-
Profit/Loss before tax and interest from each segment	**2,146.07**	**2,067.18**	**48.34**	**4,213.25**	**212.47**	**2,986.59**
Add/Less :						
i) Finance Cost	33.22	42.95	28.50	76.17	55.31	109.30
ii) Other Unallocable Expenditure net off unallocable income	-	-	-	-	-	-
Profit Before Tax	**2,112.85**	**2,024.23**	**19.84**	**4,137.08**	**157.16**	**2,877.29**
03. Segment Assets						
(i) Pharamaceutical segment	95.49	42.81	83.37	138.30	2,086.74	2,094.53
(ii) Medtech segment	1,417.75	0.23	-	1,417.98	-	1,268.49
Total Segment Assets	**1,513.24**	**43.04**	**83.37**	**1,556.28**	**2,086.74**	**3,363.01**
Unallocable Assets	-	-	-	-	-	-
Net Segment Assets	**1,513.24**	**43.04**	**83.37**	**1,556.28**	**2,086.74**	**3,363.01**
04. Segment Liabilities						
(i) Pharamaceutical segment	2,114.96	2,225.84	708.44	4,340.80	1,744.62	2,308.29
(ii) Medtech segment	-	-	-	-	-	-
Total Segment Liabilities	**2,114.96**	**2,225.84**	**708.44**	**4,340.80**	**1,744.62**	**2,308.29**
Unallocable Liabilities	-	-	-	-	-	-
Net Segment Liabilities	**2,114.96**	**2,225.84**	**708.44**	**4,340.80**	**1,744.62**	**2,308.29**
05. Capital Employed (Segment Assets- Segment Liabilities)						
(i) Pharamaceutical segment	(2,019.47)	(2,183.03)	(625.07)	(4,202.50)	342.12	(213.76)
(ii) Medtech segment	1,417.75	0.23	-	1,417.98	-	1,268.49

Note:

1.The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380001, st=GUJARAT, street=27,JASUMRATH PARK ,NIVALI PARK ROAD, ANAND KAMLI,2C7503 MAVA, 380001, l=AHMEDABAD, o=Personal, serialNumber=3be3ba15be6d4f1e2c01fa97f7f7936a:221c7e83b4d6b2129ad1a99 2c4d1ad13b2fa0dcc74244a71a4b69d71b733de, 2.5.4.20=327191b0f2f4d27cbf1d8d2126e6c7fbd7f9b8c87fcc1a2d2f0f95bb15775 1a8f, email=DAKSHESH@SHUKRAPHARMA.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:03:15 +05'30'

Dakshesh Shah
Director
DIN : 00561666

Place: Ahmedabad
Date: November 04, 2026

Independent Auditor's Review Report on quarterly and year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
SHUKRA MEDTECH LIMITED (Formerly known as SHUKRA PHARMACEUTICALS LIMITED)

1. We have reviewed the accompanying statement of unaudited standalone financial results of SHUKRA MEDTECH LIMITED (Formerly known as SHUKRA PHARMACEUTICALS LIMITED) (the "Company"), for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an Audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in as Audit. Accordingly, we do not express an audit opinion.

SHAH SANGHVI & ASSOCIATES ★ FRN. NO.: 140107W ★ CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Shah Sanghvi & Associates**
Chartered Accountants
FRN: 140107W



Ravi Shah
Partner
Membership No: 149091
UDIN: 26149091TRZLZR7851

Place: Ahmedabad
Date: November 04, 2026

SHUKRA MEDTECH LIMITED

(Formerly known as Shukra Pharmaceuticals Limited)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	Income from Operations						
I	Revenue from Operations	4,420.38	2,352.23	587.74	6,772.61	1,126.85	5,672.74
II	Other Income	57.20	53.97	171.26	111.17	282.23	458.48
	Total Income from Operations (I+II)	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,131.22**
2	**Expenses**						
	(a) Cost of materials consumed	1,598.58	125.46	1,080.81	1,724.04	955.96	1,945.02
	(b) Purchase of Stock-in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock in trade	(0.00)	(279.00)	(880.33)	(279.00)	(678.45)	(360.12)
	(d) Employee Benefit Expenses	425.88	438.87	219.33	864.75	401.82	703.72
	(e) Finance Cost	33.22	42.95	28.50	76.17	55.31	109.30
	(f) Depreciation & Amortisation Expenses	111.62	108.25	80.92	219.87	159.64	344.27
	(g) Other Expenses	525.44	152.49	209.93	677.93	357.64	510.34
	Total Expenses	**2,694.74**	**589.02**	**739.16**	**3,283.76**	**1,251.92**	**3,252.53**
3	**Profit before Tax (1-2)**	**1,782.84**	**1,817.18**	**19.84**	**3,600.02**	**157.16**	**2,878.69**
4	**Tax Expenses**						
	I. Current Tax	538.39	516.90	(0.00)	1,055.29	40.59	732.62
	II. Deferred Tax	(26.74)	4.43	(217.96)	(22.31)	(224.20)	162.15
	III. Tax of Earlier Year	-	-	-	-	-	(221.93)
5	**Net Profit for the period / year (3-4)**	**1,271.19**	**1,295.85**	**237.81**	**2,567.04**	**340.77**	**2,205.84**
6	**Other Comprehensive Income**						
	Remeasurement of defined benefit plans	-	-	-	-	-	(11.65)
	Income Tax effect	-	-	-	-	-	2.93
7	**Total Comprehensive Income for the period (9+10)**	**1,271.19**	**1,295.85**	**237.81**	**2,567.04**	**340.77**	**2,197.13**
8	**Paid up Equity Share Capital**	**4,407.87**	**4,378.79**	**4,378.79**	**4,407.87**	**4,378.79**	**4,378.79**
9	**Other equity excluding revaluation reserve**	-	-	-	-	-	**4,066.85**
10	Face Value of Equity Shares	1.00	1.00	1.00	1.00	1.00	1.00
11	Earnings per Share (of ₹ 1/- each) :						
	(a) Basic-₹	0.29	0.30	0.05	0.58	0.08	0.50
	(b) Diluted-₹	0.29	0.30	0.05	0.58	0.08	0.50

NOTES:

1. The above Unaudited Consolidated Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on November 04, 2026.
2. The Unaudited Consolidated Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Consolidated Financial Results.
3. The Unaudited Consolidated Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the half year ended September 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on September 30, 2026.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.
7. During the half year ended September 30, 2026, the Company has converted the convertible warrants issued on a preferential basis in an earlier period into equity shares. Accordingly, the equity share capital of the Company has increased pursuant to the said conversion.
8. The name of the Company has been changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited with effect from October 12, 2026.

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK,JIVRAJ PARK ROAD,,AHMEDABAD,,OCTROI NAKA ,380051, serialNumber=3b2d6a2784c84f1a0035fc0870797d0a,2.5.4.20=8fe648c1296b7d96b204d3e4, pseudonym=c2d8b198d23c7430065d88f0bb04402, 2.5.4.2=a0f2103a2f2f2d27a5514865f220dc9c7b0178d3582152cc56283f48cb1f7f7d4d, email=DAKSHESH@SHUKRAPHARMA.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:53:06 +05'30'

Dakshesh Shah
Director
DIN : 00561666

SHUKRA MEDTECH LIMITED Reg.No.- 019079

Place: Ahmedabad
Date: November 04, 2026

Unaudited Consolidated Statement of Assets and Liabilities as at September 30, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	2,090.74	2,172.31
Capital work-in-progress	2,608.68	1,190.70
	4,699.42	3,363.01
Current assets		
Inventories	2,341.55	1,390.34
Financial assets		
(i) Trade receivables	3,871.13	2,294.76
(ii) Loans & Advances	202.32	223.09
(iii) Cash and cash equivalents	1,102.14	597.63
Other current assets	5,309.79	3,875.16
	12,826.93	8,380.99
Total Assets	17,526.35	11,744.00
Equity and liabilities		
Equity		
Equity share capital	4,407.87	4,378.79
Other equity	7,380.47	4,066.85
Money received against share warrants	67.02	539.26
Total Equity	11,855.36	8,984.90
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	963.08	319.29
Deferred tax liabilities (net)	96.82	119.12
Long term provisions	33.27	11.44
	1,093.17	449.85
Current liabilities		
Financial liabilities		
(i) Borrowings	1,286.66	182.66
(ii) Trade payables	1,285.75	1,006.50
Other current liabilities	201.06	365.60
Short term provision	1,804.35	754.49
	4,577.82	2,309.24
Total liabilities	5,670.99	2,759.09
Total equity and liabilities	17,526.35	11,744.00

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,NYALI PARK ROAD ,AHMEDABAD,CICTRDI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23beb0ff1e2035fcd979797b0c421cc8d8e84857129a51d99a204d3e4, pseudonym=5d8b198023c743009d688f8b0069402, 2.5.4.20=b0f7313b2f2560213d31d8d522de3c70d1763b08215cc56283990ab32775148d, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:33:54 +05'30'

Dakshesh Shah
Director
DIN : 00561666

Place: Ahmedabad
Date: November 04, 2026

CIN : L24231GJ1993PLC019079

SHUKRA MEDTECH LIMITED

(Formerly known as Shukra Pharmaceuticals Limited)

Unaudited Consolidated Statement of Cash Flows for the period ended September 30, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	Half year ended September 30, 2026 (Unaudited)	Half year ended September 30, 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax as per statement of profit and loss	3,600.02	157.16
Adjustments for:		
Depreciation and amortisation	219.87	159.64
Interest income	(23.39)	(70.73)
Interest expense	57.03	49.09
Operating profit before working capital changes	**3,853.53**	**295.16**
Movements in working capital :		
(Increase)/decrease in trade receivables	(1,576.37)	457.68
(Increase)/decrease in inventories	(951.21)	(594.27)
(Increase)/decrease in other assets	(1,413.85)	166.74
Increase/(decrease) in trade payables	279.35	(94.16)
Increase/(decrease) in other liabilities	(148.14)	70.68
Cash generated from operations	**43.31**	**301.83**
Direct taxes (paid)/refund (net)	-	-
Net cash generated from operating activities (A)	**43.31**	**301.83**
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances and capital creditors)	(1,556.28)	(112.12)
Interest received	23.39	70.73
Net cash used in investing activities (B)	**(1,532.89)**	**(41.39)**
Cash flows from financing activities		
Proceeds from / (repayment of) borrowings	1,747.80	(43.51)
Proceeds from issue of share capital	775.56	
Money received against share warrants	(472.24)	-
Interest paid	(57.03)	(49.09)
Dividend paid	-	(43.79)
Net cash generated from / (used in) financing activities (C)	**1,994.09**	**(136.39)**
Net (decrease) / increase in cash & cash equivalents (A + B + C)	504.51	124.06
Cash and cash equivalents at the beginning of the period	597.63	1,211.77
Cash and cash equivalents at the end of the period	**1,102.14**	**1,335.82**

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

2)The figures for the previous period /year have been regrouped/ reclassified , whenever necessary.

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD, AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd979760ec421cc4df8e8485c129a31d96a2d4d3e4, postalcnym=5d8b198923c74009c6d88f8b0069402, 2.5.4.20=627313830560213d513d8d522de3c70d17f63b06215cc563699fe637751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.11.04 20:34:11 +05'30'

Dakshesh Shah
Director
DIN : 00561666

Place: Ahmedabad
Date: November 04, 2026

SHUKRA MEDTECH LIMITED

(Formerly known as Shukra Pharmaceuticals Limited)

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	9/30/2026 (Unaudited)	6/30/2026 (Unaudited)	9/30/2025 (Unaudited)	9/30/2026 (Unaudited)	9/30/2025 (Unaudited)	31-03-2026 (Audited)
01. Segment Revenue						
Net Sales/income from each segment						
(i) Pharamaceutical segment	3,226.93	2,406.20	759.00	5,633.13	1,409.08	6,129.10
(ii) Medtech segment	1,250.65	-	-	1,250.65	-	-
Total Segment Revenue	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,129.10**
Less: Inter Segment Revenue	-	-	-	-	-	-
Revenue From Operation	**4,477.58**	**2,406.20**	**759.00**	**6,883.78**	**1,409.08**	**6,129.10**
02. Segment Results						
Profit/Loss before tax and interest from each segment						
(i) Pharamaceutical segment	1,506.40	1,860.13	48.34	3,366.53	212.47	2,986.59
(ii) Medtech segment	309.66	-	-	309.66	-	-
Profit/Loss before tax and interest from each segment	**1,816.06**	**1,860.13**	**48.34**	**3,676.19**	**212.47**	**2,986.59**
Add/Less :						
i) Finance Cost	33.22	42.95	28.50	76.17	55.31	109.30
ii) Other Unallocable Expenditure net off unallocable income	-	-	-	-	-	-
Profit Before Tax	**1,782.84**	**1,817.18**	**19.84**	**3,600.02**	**157.16**	**2,877.29**
03. Segment Assets						
(i) Pharamaceutical segment	23.91	114.39	83.37	138.30	2,086.74	2,094.53
(ii) Medtech segment	1,417.75	0.23	-	1,417.98	-	1,268.49
Total Segment Assets	**1,441.66**	**114.62**	**83.37**	**1,556.28**	**2,086.74**	**3,363.01**
Unallocable Assets	-	-	-	-	-	-
Net Segment Assets	**1,441.66**	**114.62**	**83.37**	**1,556.28**	**2,086.74**	**3,363.01**
04. Segment Liabilities						
(i) Pharamaceutical segment	2,169.22	2,408.60	708.44	4,577.82	1,744.62	2,308.29
(ii) Medtech segment	-	-	-	-	-	-
Total Segment Liabilities	**2,169.22**	**2,408.60**	**708.44**	**4,577.82**	**1,744.62**	**2,308.29**
Unallocable Liabilities	-	-	-	-	-	-
Net Segment Liabilities	**2,169.22**	**2,408.60**	**708.44**	**4,577.82**	**1,744.62**	**2,308.29**
05. Capital Employed (Segment Assets- Segment Liabilities)						
(i) Pharamaceutical segment	(2,145.31)	(2,294.21)	(625.07)	(4,439.52)	342.12	(213.76)
(ii) Medtech segment	1,417.75	0.23	-	1,417.98	-	1,268.49

Note:

1.The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

SHUKRA MEDTECH LIMITED Reg.No.- 019079

For and on behalf of the Board of Directors of
SHUKRA MEDTECH LIMITED (FORMERLY KNOWN AS SHUKRA PHARMACEUTICALS LIMITED)

DAKSHESH RAMESHCHANDRA SHAH
Dakshesh Shah
Director
DIN : 00561666

Place: Ahmedabad
Date: November 04, 2026

Independent Auditor's Review Report on quarterly and year to date Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
SHUKRA MEDTECH LIMITED (Formerly known as SHUKRA PHARMACEUTICALS LIMITED)

1. We have reviewed the accompanying statement of unaudited consolidated financial results of SHUKRA MEDTECH LIMITED (Formerly known as SHUKRA PHARMACEUTICALS LIMITED) ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement"), attached herewith being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Listing Regulations"), as amended (the "Listing Regulations").

2. Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. A review of Interim Financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the SEBI Listing Regulations, as amended, to the extent applicable.

4. The Statement includes the result of the following entities:

   - **Holding Company**
     a) SHUKRA PHARMACEUTICALS LIMITED

SHAH SANGHVI & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ FRN. NO.: 140107W

- **Subsidiaries / Body Corporates**
  a) SHUKRA DIABETES TECHNOLOGIES PRIVATE LIMITED
  b) SHUKRA HEALTH TECH PRIVATE LIMITED
  c) SHUKRA ROBOTICS PRIVATE LIMITED
  d) SHUKRA WOUNDCARE PRIVATE LIMITED
  e) RADIANCE AESTHETICS PRIVATE LIMITED
  f) SHUKRA COMBAT MEDICAL SUPPORT PVT LTD.
  g) SHUKRA DEFENCE PRIVATE LIMITED
  h) SHUKRA EMERGICARE AND VIRTUAL AUTOPSY

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. 8 (eight) subsidiaries, whose unaudited interim financial results and other unaudited financial information includes total assets (before consolidation adjustments) of ₹ 37.20 lakh as at September 30, 2026, total revenue (before consolidation adjustments) of ₹ 0 and ₹ 0, total net profit after tax (before consolidation adjustments) of ₹ (329.99) lakh and ₹ (537.13) lakh, total comprehensive income (before consolidation adjustments) of ₹ (329.99) lakh and ₹ (537.13) lakh for the quarter ended September 30, 2026, and the period ended on that date respectively as considered in the Statement have been approved and furnished to us by the Management of the Holding Company and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on such unaudited financial results and financial information. According to the information and explanation given to us by the Management, this unaudited interim financial results/information are not material to the Group.

   Our conclusion on the statement is not modified in respect of the above matters with respect to our reliance on the unaudited interim financial result and information provided by the Management.

For **Shah Sanghvi & Associates**
Chartered Accountants
FRN: 140107W



Ravi Shah
Partner
Membership No: 149091
UDIN: 26149091LXPTNH8356

Place: Ahmedabad
Date: November 04, 2026